Skip to main content
SpringerLink
Log in

Use and Comparative Properties of the Three Prototypical Calcium Antagonists in Ischemic Heart Disease, Including Recommendations Based on an Analysis of 41 Trials

  • Chapter
Clinical Use of Calcium Channel Antagonist Drugs

  • 56 Accesses

Summary

An analysis of 41 trials of angina of all varieties confirms that calcium antagonists are an important advance and are now established therapy for these syndromes. In effort angina, verapamil in a dose of 360–480 mg daily is better than propranolol in standard doses. Although nifedipine is highly effective against vasospastic angina, its use in threatened myocardial infarction or severe unstable angina is not supported by recent studies, unless combined with a beta-blocker. Diltiazem has recently been tested with apparent benefit in non-Q-wave myocardial infarction. Otherwise, these calcium antagonist agents all seem to have approximate equipotency in clinical ischemic syndromes including effort and vasospastic angina. Subjective side effects seem most troublesome in the case of nifedipine. All three calcium antagonists, especially nifedipine, have been successfully combined with beta-blocker therapy, yet occasional additive negative inotropic or chronotropic or dromotropic interactions may occur when verapamil or diltiazem is added to beta-blockade, and occasionally the direct negative inotropic potential of nifedipine may become evident. The choice between the calcium antagonists is determined not only by the clinical picture but also by the anticipated side effects in a given patient and by the overall cardiovascular status. In patients with supraventricular tachycardias or sinus tachycardia, verapamil or diltiazem is preferred, whereas in patients with a resting bradycardia or borderline heart failure nifedipine is likely to be chosen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Thaulow E, Guth BD, Ross J Jr: Role of calcium channel blockers in experimental exercise-induced ischemia. Cardiouasc Drugs Ther 1987; 1:503–512.

    Google Scholar 

  2. Nay1er WG. Review. Calcium antagonists and the ischemic myocardium. Int J Cardiol 1987; 15:267–285.

    PubMed  CAS  Google Scholar 

  3. Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987; 59:84B–94B.

    PubMed  CAS  Google Scholar 

  4. Nayler WG, Ferrari R, Williams A. Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 1980; 46:242–248.

    PubMed  CAS  Google Scholar 

  5. Weishaar RE, Bing RJ. The beneficial effect of a calcium channel blocker, diltiazem, on the ischemic-reperfused heart. J Mol Cell Cardiol 1980; 12:993–1009.

    PubMed  CAS  Google Scholar 

  6. Nayler WG: Protection of the myocardium against post-ischemic reperfusion damage. The combined effect of hypothermia and nifedipine. J Thorac Cardiovasc Surg 1982; 84:897–905.

    PubMed  CAS  Google Scholar 

  7. Nayler WG, Grau A, Slade A: A protective effect of verapamil on hypoxic heart muscle. Cardiovasc Res 1976; 10:650–662.

    PubMed  CAS  Google Scholar 

  8. Watts JA, Maiorano LJ, Maiorano PC. Protection by verapamil of globally ischemic rat hearts: Energy preservation, a partial explanation. J Mol Cell Cardiol 1985;17:797–804.

    PubMed  CAS  Google Scholar 

  9. De Jong JW, Harmsen E, De Tombe P, et al. Nifedipine reduces adenine nucleotide breakdown in ischemic rat heart. Eur J Pharmacol 1982; 81:89–96.

    PubMed  Google Scholar 

  10. Knoch G, Schlepper M, Witzleb E: Isoptin-a clinical study using normal subjects and patients with coronary disease. Med Klin 1963; 58:1485–1491.

    PubMed  CAS  Google Scholar 

  11. Tschirdewahn B, Klepzig H. Clinical studies on the effect of Isoptin and Isoptin S in patients with coronary insufficiency (in German). Deutsche Med Wochensch 1963; 88:1702–1710.

    CAS  Google Scholar 

  12. Sandler G, Clayton GA, Thornicroft SG. Clinical evaluation of verapamil in angina pectoris. Br Med J 1968; 3:224–227.

    PubMed  CAS  Google Scholar 

  13. Livesley B, Catley PF, Campbell RC: Double-blind evaluation of verapamil, propranolol and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1973; 1:375–378.

    PubMed  CAS  Google Scholar 

  14. Arnman K, Ryden L. Comparison of metoprolol and verapamil in the treatment of angina pectoris (abstr). Am J Cardiol 1982; 49:821.

    PubMed  CAS  Google Scholar 

  15. Dawson JR, Whitaker NHG, Sutton GC. Calcium antagonists in chronic stable angina. Comparison of verapamil and nifedipine. Br Heart J 1981; 46:508–512.

    PubMed  CAS  Google Scholar 

  16. Andreassen F, Boye E, Christoffersen E, et al. Assessment of verapamil in the treatment of angina pectoris. Eur J Cardiol 1975; 2/4:443–452.

    Google Scholar 

  17. Subramanian VB, Lahiri A, Paramasivan R, et al. Verapamil in chronic stable angina. Lancet 1980; i:841–840.

    Google Scholar 

  18. Hecht HS, Clew CYC, Burnam MH, et al. Verapamil in chronic stable angina: Amelioration of pacing-induced abnormalities of left ventricular ejection fraction, regional wall motion, lactate metabolism and hemodynamics. Am J Cardiol 1981; 48:536–544.

    PubMed  CAS  Google Scholar 

  19. Subramanian VB, Bowles MJ, Khurmi NS, et al. Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil. Am J Cardiol 1982; 50:1173–1179.

    PubMed  CAS  Google Scholar 

  20. Subramanian VB. Calcium Antagonists in Chronic Stable Angina Pectoris. Amsterdam: Excerpta Medica, 1983;97–116, 217–229.

    Google Scholar 

  21. Weiner DA, Klein MD, Cutler SS. Efficacy of sustained-release verapamil in chronic stable angina pectoris. Am J Cardiol 1987; 59:215–218.

    PubMed  CAS  Google Scholar 

  22. Johnson SM, Mauritson DR, Corbett JR, et al. Doubleblind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981; 71:443–451.

    PubMed  CAS  Google Scholar 

  23. Sadick N, Tan ATH, Fletcher PJ, et al: A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina. Circulation 1982; 66:574–579.

    PubMed  CAS  Google Scholar 

  24. Frishman WH, Klein NA, Strom JA, et al. Superiority of verapamil to propranolol in stable angina pectoris: A double-blind randomized crossover trial. Circulation 1982; 65(Suppl I):51–59.

    Google Scholar 

  25. Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 1981; 48:131–139.

    PubMed  CAS  Google Scholar 

  26. Pine MB, Citron D, Bailly DJ, et al. Verapamil versus placebo in relieving stable angina pectoris. Circulation 1982; 65:17–22.

    PubMed  CAS  Google Scholar 

  27. Khurmi NS, Raftery EB. Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine tiapamil and verapamil) in patients with chronic stable angina pectoris. Cardiovasc Drugs Ther 1987; 1:81–87.

    PubMed  CAS  Google Scholar 

  28. Johnston DL, Lesoway R, Humen DP, et al. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: A placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol 1985;55:680–687.

    PubMed  CAS  Google Scholar 

  29. Winniford MD, Fulton KL, Corbett JR, et al. Propranololverapamil versus propranolol-nifedipine in severe angina pectoris of effort: A randomized, double-blind crossover study. Am J Cardiol 1985; 55:281–285.

    PubMed  CAS  Google Scholar 

  30. Findlay IN, MacLeod K, Gillen G, et al. A double-blind placebo-controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. Br Heart J 1987; 57:336–343.

    PubMed  CAS  Google Scholar 

  31. Packer M, Meiler J, Medina N, et al. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982; 65:660–668.

    PubMed  CAS  Google Scholar 

  32. Patton JN, Vlietstra RE, Frye RL. Randomized, placebo-controlled study of the effect of verapamil on exercise hemodynamics in coronary artery disease. Am J Cardiol 1984; 53:674–678.

    PubMed  CAS  Google Scholar 

  33. Rouleau J-L, Chatterjee K, Ports TA, et al. Mechanism of relief of pacing-induced angina with oral verapamil: Reduced oxygen demand. Circulation 1983; 67:94–100.

    PubMed  CAS  Google Scholar 

  34. Singh BN, Chew CC, Josephson MA, et al. Pharmacologic and hemodynamic mechanisms underlying the anti-anginal actions of verapamil. Am J Cardiol 1982; 50:886–893.

    PubMed  CAS  Google Scholar 

  35. Urquhart J, Epstein SE, Patterson RE. Comparative effects of calcium-channel blocking agents on left ventricular function during acute ischemia in dogs with and without congestive heart failure. Am J Cardiol 1985; 55:10B–16B.

    PubMed  CAS  Google Scholar 

  36. Smith HJ, Goldstein RA, Griffith JM. Regional contractility. Selective depression of ischemic myocardium by verapamil. Circulation 1976; 54:629–635.

    PubMed  CAS  Google Scholar 

  37. Lumley P, Robertson MJ. Experimental conditions can differentially affect calcium channel blocker potency in guinea-pig cardiac muscle. Presentation to NY Acad Sci, Feb 1987.

    Google Scholar 

  38. Chew CYC, Brown G, Singh BN, et al. Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action. Am J Cardiol 1983; 51:699–705.

    PubMed  CAS  Google Scholar 

  39. Heusch G, Guth BD, Seitelberger R, et al. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation 1987; 75:482–490.

    PubMed  CAS  Google Scholar 

  40. Apstein CS, Grossman W. Opposite initial effects of supply and demand ischemia on left ventricular diastolic compliance: The ischemia-diastolic paradox. J Mol Cell Cardiol 1987; 19:119–128.

    PubMed  CAS  Google Scholar 

  41. Bonow RO, Leon MB, Rosing DR, et al. Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in patients with coronary artery disease: Radionuclide angiographic studies at rest and during exercise. Circulation 1981; 65:1337–1350.

    Google Scholar 

  42. Bolognesi R, Cucchini F, Manca C, et al. Effects of verapamil and nifedipine on rate of left ventricular relaxation in coronary artery disease patients with normal systolic function. Presentation to NY Acad Sci, Feb 1987.

    Google Scholar 

  43. Atterhog JH, Ekelund LG, Melin AL: Effect of nifedipine on exercise tolerance in patients with angina pectoris. Eur J Clin Pharmacol 1975; 8:125–130.

    PubMed  CAS  Google Scholar 

  44. Ardissino D, de Servi S, Salerno JA, et al. Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced angina pectoris. Eur Heart J 1983; 4:873–881.

    PubMed  CAS  Google Scholar 

  45. Chaitman BR, Wagniart P, Pasternac A, et al. Improved exercise tolerance after propranolol, diltiazem or nifedipine in angina pectoris: Comparison at 1, 3 and 8 hours and correlation with plasma drug concentration. Am J Cardiol 1984; 53:1–9.

    PubMed  CAS  Google Scholar 

  46. Deanfield J, Wright C, Krikler S, et al. Cigarette smoking and the treatment of angina with propranolol, atenolol and nifedipine. N Engl J Med 1984; 310:951–954.

    PubMed  CAS  Google Scholar 

  47. Winniford MD, Jansen DE, Reynolds GA, et al. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol 1987; 59:203–207.

    PubMed  CAS  Google Scholar 

  48. Sherman LG, Liang C-S. Nifedipine in chronic stable angina: A double-blind placebo-controlled crossover trial. Am J Cardiol 1983; 51:706–711.

    PubMed  CAS  Google Scholar 

  49. Lynch P, Dargie H, Krikler S, et al. Objective assessment of antianginal treatment: A double-blind comparison of propranolol, nifedipine and their combination Br Med J 1980; 281:184–187.

    PubMed  CAS  Google Scholar 

  50. Mueller HS, Chahine RA. Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina. Am J Med 1981; 71:645–657.

    PubMed  CAS  Google Scholar 

  51. Uusitalo A, Arstila M, Bae EA, et al. Metoprolol, nifedipine and the combination in stable effort angina pectoris. Am J Cardiol 1986; 57:733–737.

    PubMed  CAS  Google Scholar 

  52. Findlay IN, MacLeod K, Ford M, et al. Treatment of angina pectoris with nifedipine and atenolol: Efficacy and effect on cardiac function. Br Heart J 1986; 55:240–245.

    PubMed  CAS  Google Scholar 

  53. Higginbotham MB, Morris KG, Coleman RE, et al. Comparison of nifedipine alone with propranolol alone for stable angina pectoris including hemodynamics at rest and during exercise. Am J Cardiol 1986; 57:1022–1028.

    PubMed  CAS  Google Scholar 

  54. Jariwalla AG, Anderson EG. Side effects of drugs. Production of ischaemic cardiac pain by nifedipine. Br Med J 1978; 1:1181–1182.

    PubMed  CAS  Google Scholar 

  55. Stone PH, Muller JE, Turi ZG, et al. Efficacy of nifedipine therapy in patients with refractory angina pectoris: Significance of the presence of coronary vasospasm. Am Heart J 1983; 106:644–652.

    PubMed  CAS  Google Scholar 

  56. Deanfield J, Wright C, Fox K. Treatment of angina pectoris with nifedipine: Importance of dose titration. Br Med J 1983; 286:1467–1470.

    CAS  Google Scholar 

  57. Terry RW. Nifedipine therapy in angina pectoris: Evaluation of safety and side-effects. Am Heart J 1982; 104:681–689.

    PubMed  CAS  Google Scholar 

  58. Kiowski W, Erne P, Bertel O, et al. Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol 1986; 7:344–348.

    PubMed  CAS  Google Scholar 

  59. Van Wezel HB, Bovili JG, Koolen JJ, et al. Myocardial metabolism and coronary sinus blood flow during coronary artery surgery: Effects of nitroprusside and nifedipine. Am Heart J 1987; 113:266–273.

    PubMed  Google Scholar 

  60. Schanzenbacher P, Liebau G, Deeg P, et al. Effect of intravenous and intracoronary nifedipine on coronary blood flow and myocardial oxygen consumption. Am J Cardiol 1983; 51:712–717.

    PubMed  CAS  Google Scholar 

  61. Schanzenbacher P, Gottfert G, Liebau G, et al. Coronary hemodynamic and metabolic effects of nifedipine in patients with coronary artery disease treated with beta-blocking drugs. Am J Cardiol 1985; 55:33–36.

    PubMed  CAS  Google Scholar 

  62. Sorkin EM, Clissold SP Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30:182–274.

    PubMed  CAS  Google Scholar 

  63. Emanuelsson H, Holmberg S. Mechanisms of angina relief after nifedipine: A hemodynamic and myocardial metabolic study. Circulation 1983; 68:124–130.

    PubMed  CAS  Google Scholar 

  64. Specchia G, de Servi S, Falcone C, et al. Effects of nifedipine on coronary hemodynamic findings during exercise in patients with stable exertional angina. Circulation 1983; 68:1035–1043.

    PubMed  CAS  Google Scholar 

  65. Feldman RL, Hill JA, Conti R, et al. Effect of nifedipine on coronary hemodynamics in patients with left anterior descending coronary occlusion. J Am Coll Cardiol 1985; 5: 318–325.

    PubMed  CAS  Google Scholar 

  66. Kramer PH, Chatterjee K, Schwartz A, et al. Alterations in angina threshold with nifedipine during pacing induced angina. Br Heart J 1984; 52:308–313.

    PubMed  CAS  Google Scholar 

  67. Schulz W, Jost S, Kober G, et al. Relation of antianginal efficacy of nifedipine to degree of coronary arterial narrowing and to presence of coronary collateral vessels. Am J Cardiol 1985; 55:26–32.

    PubMed  CAS  Google Scholar 

  68. Lichtlen PR, Engel H-J, Rafflenbeul W. Calcium entry blockers, especially nifedipine, in angina of effort: possible mechanisms and clinical implications. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984; 221–236.

    Google Scholar 

  69. Wagniart P, Ferguson RJ, Chaitman BR, et al. Increased exercise tolerance and reduced electrocardiographic ischemia with diltiazem in patients with stable angina pectoris. Circulation 1982; 66:23–28.

    PubMed  CAS  Google Scholar 

  70. Anderson JL, Wagner JM, Datz FL, et al. Comparative effects of diltiazem, propranolol, and placebo on exercise performance using radionuclide ventriculography in patients with symptomatic coronary artery disease: Results of a double-blind, randomized, crossover study. Am Heart J 1984; 107:698–706.

    PubMed  CAS  Google Scholar 

  71. Hossack KF, Pool PE, Steele P et al: Efficacy of diltiazem in angina of effort: A multicenter trial. Am J Cardiol 1982; 49:567–572.

    PubMed  CAS  Google Scholar 

  72. Hung J, Lamb IH, Connolly SJ, et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo controlled study. Circulation 1983; 68:560–567.

    PubMed  CAS  Google Scholar 

  73. Lindenberg BS, Weiner DA, McCabe CH, et al. Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 1983; 2:1129–1133.

    PubMed  CAS  Google Scholar 

  74. Go M, Hollenberg M. Improved efficacy of high-dose versus medium-and low-dose diltiazem therapy for chronic stable angina pectoris. Am J Cardiol 1984; 53:669–673.

    PubMed  Google Scholar 

  75. Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985; 71:951–957.

    PubMed  CAS  Google Scholar 

  76. Khurmi NS, Bowles MJ, O’Hara MJ, et al. Long-term efficacy of diltiazem assessed with multistage graded exercise tests in patients with chronic stable angina pectoris. Am J Cardiol 1984; 54:738–743.

    PubMed  CAS  Google Scholar 

  77. Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol 1986; 57:6–9.

    PubMed  CAS  Google Scholar 

  78. Joyal M, Cremer K, Pieper J, et al. Effects of diltiazem during tachycardia-induced angina pectoris. Am J Cardiol 1986; 57:10–14.

    PubMed  CAS  Google Scholar 

  79. Lahiri A, Dasgupta P, Rodrigues EA, et al. Acute drug withdrawal in patients with stable angina on long term treatment with verapamil. In: Raftery EB, ed. Verapamil SR. Langhorne: ADIS Press International, 1987; 18–29.

    Google Scholar 

  80. Leisten L, Kuhlmann J, Ebner F. Side effects and pharmacodynamic interactions. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (nifedipine). Stuttgart: Schattauer, 1986; 279–314.

    Google Scholar 

  81. Gottlieb SO, Ouyang P, Achuff SC, et al. Acute nifedipine withdrawal: Consequences of preoperative and late cessation of therapy in patients with prior unstable angina. J Am Coll Cardiol 1984; 4:382–388.

    PubMed  CAS  Google Scholar 

  82. Gill JB, Cairns JA, McEwan MP. Improved left ventricular performance during exercise with verapamil or nifedipine in patients with chronic stable angina. Am Heart J 1987; 113:700–707.

    PubMed  CAS  Google Scholar 

  83. Schurtz CI, Lesbre JP, Kalisa A, et al. Intérêt des inhibiteurs calciques dans l’angor d’effort stable: Diltiazem versus nifedipine. Ann Cardiol Angeiol 1983; 32:337–341.

    CAS  Google Scholar 

  84. Chaffman M, Brogden RN. Diltiazem: A review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29:387–454.

    PubMed  CAS  Google Scholar 

  85. Weiner DA, McCabe CH, Cutler SS, et al. The efficacy and safety of high-dose verapamil and diltiazem in the long-term treatment of stable exertional angina. Clin Cardiol 1984; 7:648–653.

    PubMed  CAS  Google Scholar 

  86. Landmark K. Antihypertensive and metabolic effects of long-term therapy with nifedipine slow-release tablets. J Cardiovasc Pharmacol 1985; 7:12–17.

    PubMed  CAS  Google Scholar 

  87. Feigl EO. Coronary physiology. Physiol Rev 1983; 63:1–205.

    PubMed  CAS  Google Scholar 

  88. Opie LH, Maseri A. Vasospastic angina. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (nifedipine). Stuttgart: Schattauer, 1986; 231–258.

    Google Scholar 

  89. Young MA, Vatner SF. Regulation of large coronary arteries. Circ Res 1986; 59:579–596.

    PubMed  CAS  Google Scholar 

  90. Rapaport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein dephosphorylation. Nature 1983; 306:174–176.

    Google Scholar 

  91. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983; 53:557–573.

    PubMed  CAS  Google Scholar 

  92. Rubanyi G, Vanhoutte PM. Inhibitors of prostaglandin synthesis augment beta-adrenergic responsiveness in canine coronary arteries. Circ Res 1985; 56:117–125.

    PubMed  CAS  Google Scholar 

  93. Rapaport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: Role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res 1983; 9:281–296.

    Google Scholar 

  94. Yasue H. Coronary artery spasm and calcium ions. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984; 117–128.

    Google Scholar 

  95. Prinzmetal M, Kennamer R, et al. Angina pectoris. I. A variant form of angina pectoris. Am J Med 1959; 27:375–388.

    PubMed  CAS  Google Scholar 

  96. Maseri A, Severi S, De Nés M, et al. “Variant” angina: One aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary artériographic findings in 138 patients. Am J Cardiol 1978; 42:1019–1035.

    PubMed  CAS  Google Scholar 

  97. Pepine CJ, Feldman RL, Hill JA, et al. Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine and verapamil. Am Heart J 1983; 106:1341–1347.

    PubMed  CAS  Google Scholar 

  98. Previtali M, Panciroli C, Ardissino D, et al. Spontaneous remission of variant angina documented by Holter monitoring and ergonovine testing in patients treated with calcium antagonists. Am J Cardiol 1987; 59:235–240.

    PubMed  CAS  Google Scholar 

  99. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary artery spasm. Experience in 127 patients. N Engl J Med 1980; 302:1269–1273.

    PubMed  CAS  Google Scholar 

  100. Kimura E, Kishida H. Treatment of variant angina with drugs: A survey of 11 cardiology institutes in Japan. Circulation 1981; 63:844–848.

    PubMed  CAS  Google Scholar 

  101. Waters DD, Miller DD, Szlachcic J. Factors influencing the long-term prognosis of treated patients with variant angina. Circulation 1983; 68:258–265.

    PubMed  CAS  Google Scholar 

  102. Rich S, Ford LE, Al-Sadir J. The angiographic effect of ergonovine and nifedipine in coronary artery spasm. Circulation 1980; 62:1127–1130.

    PubMed  CAS  Google Scholar 

  103. Tiefenbrunn AJ, Sobel BE, Gowda S, et al. Nifedipine blockade of ergonovine-induced coronary arterial spasm: Angiographic documentation. Am J Cardiol 1981; 48:184–187.

    PubMed  CAS  Google Scholar 

  104. Previtali M, Salerno JA, Tavazzi L, et al. Treatment of angina at rest with nifedipine: A short-term controlled study. Am J Cardiol 1980; 45:825–830.

    PubMed  CAS  Google Scholar 

  105. Shick EC, Liang CS, Heuler FA, et al. Randomized withdrawal from nifedipine: Placebo-controlled study in patients with coronary artery spasm. Am Heart J 1982; 104:690–697.

    Google Scholar 

  106. Winniford MD, Johnson SM, Mauritson DR, et al. Verapamil therapy for Prinzmetal’s variant angina: Comparison with placebo and nifedipine. Am J Cardiol 1982; 50:913–918.

    PubMed  CAS  Google Scholar 

  107. Prida XE, Gelman JS, Feldman RL, et al. Comparison of diltiazem and nifedipine alone and in combination in patients with coronary artery spasm. J Am Coll Cardiol 1987; 9:412–419.

    PubMed  CAS  Google Scholar 

  108. Waters DD, Theroux P, Szlachcic J, et al. Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. Am J Cardiol 1981; 48:123–130.

    PubMed  CAS  Google Scholar 

  109. Ginsburg R, Lamb IH, Schroeder JS, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982; 103:44–48.

    PubMed  CAS  Google Scholar 

  110. Hill JA, Feldman RL, Pepine CJ, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm. Am J Cardiol 1982; 49:431–438.

    PubMed  CAS  Google Scholar 

  111. Winniford MD, Gabliani G, Johnson SM, et al. Concomitant calcium antagonists plus isosorbide dinitrate therapy for markedly active variant angina. Am Heart J 1984; 108: 1269–1273.

    PubMed  CAS  Google Scholar 

  112. Parodi O, Simonetti I, Michelassi C, et al. Comparison of verapamil and propranolol therapy for angina pectoris at rest: A randomized, multiple crossover, controlled trial in the coronary care unit. Am J Cardiol 1986; 57:899–906.

    PubMed  CAS  Google Scholar 

  113. Tilmant PY, Lablanche JM, Thieuleux FA, et al. Detrimental effect of propranolol in patients with coronary arterial spasm contered by combination with diltiazem. Am J Cardiol 1983; 52:230–233.

    PubMed  CAS  Google Scholar 

  114. Robertson RM, Wood AJ, Vaughan WK, et al. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982; 65:281–285.

    PubMed  CAS  Google Scholar 

  115. Lette J, Gagnon RM, Lemire JG, et al. Rebound of vasospastic angina after cessation of long-term treatment with nifedipine. Can Med Assoc J 1984; 130:1169–1171.

    PubMed  CAS  Google Scholar 

  116. Moses JW, Wertheimer JH, Bodenheimer MM, et al. Efficacy of nifedipine in rest angina refractory to propranolol and nitrates in patients with obstructive coronary artery disease. Ann Intern Med 1981; 94:425–429.

    PubMed  CAS  Google Scholar 

  117. Muiesan G, Agabiti-Rosei E, Romanelli G, et al: Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986; 57:44D–49D.

    PubMed  CAS  Google Scholar 

  118. Schroeder JS, Walker SD, Skalland L, et al. Absence of rebound from diltiazem therapy in Prinzmetal’s variant angina. J Am Coll Cardiol 1985; 6:174–178.

    PubMed  CAS  Google Scholar 

  119. Yasue H, Omote S, Takizawa A, et al. Circadian variation of exercise capacity in patients with Prinzmetal’s variant angina: Role of exercise-induced coronary artery spasm. Circulation 1979; 59:938–947.

    PubMed  CAS  Google Scholar 

  120. Yasue H, Omote S, Takizawa A, et al. Exertional angina pectoris caused by coronary artery spasm: Effects of various drugs. Am J Cardiol 1979; 43:647–652.

    PubMed  CAS  Google Scholar 

  121. Opie LH, Jee L, White D. Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. Am Heart J 1982; 104:606–612.

    PubMed  CAS  Google Scholar 

  122. Stone PH. Calcium antagonists for Prinzmetal’s variant angina, unstable angina and silent myocardial ischemia. Therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol 1987; 59:101B–115B.

    PubMed  CAS  Google Scholar 

  123. Glazier JJ, Chierchia S, Brown MJ, et al. Importance of generalized defective perception of painful stimuli as a cause of silent myocardial ischemia in chronic stable angina pectoris. Am J Cardiol 1986; 58:667–672.

    PubMed  CAS  Google Scholar 

  124. Quyyumi AA, Wright C, Fox K. Ambulatory electrocardiographic ST segment changes in healthy volunteers. Br Heart J 1983; 50:460–464.

    PubMed  CAS  Google Scholar 

  125. Cocco G, Strozzi C, Chu D, et al. Therapeutic effects of pindolol and nifedipine in patients with stable angina pectoris and asymptomatic resting ischemia. Eur J Cardiol 1979; 10:59–69.

    PubMed  CAS  Google Scholar 

  126. Quyyumi AA, Wright C, Mockus L, et al. Effect of partial agonist activity in β-blockers in severe angina pectoris: A double-blind comparison of pindolol and atenolol. Br Med J 1984; 289:951–953.

    CAS  Google Scholar 

  127. Parodi O, Simonetti I, L’Abbate A, et al. Verapamil versus propranolol for angina at rest. Am J Cardiol 1982; 50:923–928.

    PubMed  CAS  Google Scholar 

  128. Rizzon P, Scrutinio D, Mangini SG, et al. Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest. Eur Heart J 1986; 7:67–76.

    PubMed  CAS  Google Scholar 

  129. Pepine CJ, Feldman RL, Ludbrook P, et al. Left ventricular dyskinesia reversed by intravenous nitroglycerin: A manifestation of silent myocardial ischemia. Am J Cardiol 1986; 58:38B–42B.

    PubMed  CAS  Google Scholar 

  130. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986; 314:1214–1219.

    PubMed  CAS  Google Scholar 

  131. Maseri A, Chierchia S, Kaski JC. Mixed angina pectoris. Am J Cardiol 1985; 56:30E–33E.

    PubMed  CAS  Google Scholar 

  132. Andre-Fouet X, Usdin JP, Gayet CH, et al. Comparison of short-term efficacy of diltiazem and propranolol in unstable angina at rest-randomized trial in 70 patients. Eur Heart J 1983; 4:691–698.

    PubMed  CAS  Google Scholar 

  133. Parodi O, Maseri A, Simonetti I. Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit. Br Heart J 1979; 41:167–174.

    PubMed  CAS  Google Scholar 

  134. Capucci A, Bassein L, Bracchetti D, et al. Propranolol v. verapamil in the treatment of unstable angina. A double-blind cross-over study. Eur Heart J 1983; 4:148–154.

    PubMed  CAS  Google Scholar 

  135. Moll MG, Dominguez JM, Obrador D, et al. Nifedipine (N) vs. propranolol (P) in unstable angina (UA): A prospective randomized study (abstr). Eur Heart J 1984; 5(Suppl 1):238.

    Google Scholar 

  136. Rahimtoola SH, Nunley D, Grunkemeier G, et al. Ten year survival after coronary artery bypass surgery for unstable angina. N EnglJ Med 1983; 308:676–681.

    CAS  Google Scholar 

  137. Gazes PC, Mobley EM, Faris HM, et al. Preinfarctional (unstable) angina-a prospective study-ten year follow-up. Prognostic significance of electrocardiographic changes. Circulation 1973; 48:331–337.

    PubMed  CAS  Google Scholar 

  138. Fischi SJ, Herman MV, Gorlin R: The intermediate coronary syndrome. Clinical, angiographic and therapeutic aspects. N Engl J Med 1973; 288:1193–1198.

    Google Scholar 

  139. Conti, CR, Brawley RK, Griffith LSC, et al. Unstable angina pectoris: Morbidity and mortality in 57 consecutive patients evaluated angiographically. Am J Cardiol 1973; 32:745–750.

    PubMed  CAS  Google Scholar 

  140. HINT Research Group (Holland Interuniversity Nifedipine/Metroprolol Trial): Early treatment of unstable angina in the coronary care unit: A randomised double-blind placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56:400–413.

    Google Scholar 

  141. Theroux P, Taeymans Y, Morissette D, et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985; 5:717–722.

    PubMed  CAS  Google Scholar 

  142. Forrester JS, Litvack F, Grundfest W, et al. A perspective of coronary disease seen through the arteries of living man. Circulation 1987; 75:505–513.

    PubMed  CAS  Google Scholar 

  143. Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol 1975; 36:938–953.

    PubMed  CAS  Google Scholar 

  144. Hugenholtz PG: Unstable angina pectoris. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart: Schattauer, 1986; 187–229.

    Google Scholar 

  145. Muller JE, Turi ZG, Pearle DL, et al: Nifedipine and conventional therapy for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984; 69:728–739.

    PubMed  CAS  Google Scholar 

  146. Muller J, Morrison J, Stone PH, et al: Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized double-blind placebo-controlled comparison. Circulation 1984; 69:740–747.

    PubMed  CAS  Google Scholar 

  147. Yokoyama M, Koizumi T, Fujitani K, et al. Adverse response to nifedipine in unstable angina pectoris. Chest 1982; 81:646–648.

    PubMed  CAS  Google Scholar 

  148. Sia STB, MacDonald PS, Triester B, et al. Aggravation of myocardial ischemia by nifedipine. Med J Aust 1985; 142:48–50.

    PubMed  CAS  Google Scholar 

  149. Gerstenblith G, Ouyang P, Achuff SC, et al. Nifedipine in unstable angina: A double-blind randomized trial. N Engl J Med 1982; 306:885–889.

    PubMed  CAS  Google Scholar 

  150. Scheidt S, Frishman WH, Packer M, et al. Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. Am J Cardiol 1982; 50:1185–1190.

    PubMed  CAS  Google Scholar 

  151. Gordon GD, Mabin TA, Isaacs S, et al: Hemodynamic effects of sublingual nifedipine in acute myocardial infarction. Am J Cardiol 1984; 53:1228–1232.

    PubMed  CAS  Google Scholar 

  152. Gordon GD, Mabin TA, Lloyd EA, et al. Nifedipine in acute myocardial infarction. In: Lichtlen PR, ed. Sixth International Adalat Symposium. Amsterdam: Excerpta Medica, 1986; 271–279.

    Google Scholar 

  153. Simes PA, Overskeid K, Pedersen TR, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 1984; 70:638–644.

    Google Scholar 

  154. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: The Trent study. Br Med J 1986; 293:1204–1208.

    CAS  Google Scholar 

  155. Branagan JP, Walsh K, Kelly P, et al. Effect of early treatment with nifedipine in suspected acute myocardial infarction. Eur Heart J 1986; 7:858–865.

    Google Scholar 

  156. Wolf R, Habel F, Witt E, et al. Wirkung von Verapamil auf die Hemodynamik und Grosse des akuten Myokardinfarkts. Herz 1977; 2:110–119.

    Google Scholar 

  157. Bussmann WD, Scher W, Grungras M. Reduktion der CK und CKMB-infarktgrosse durch Verapamil. Deutsche Med Wochschr 1983; 108:1047–1053.

    CAS  Google Scholar 

  158. Thuesen L, Jorgenson JR, Kvistgaard HJ, et al. Effect of verapamil on enzyme release after early intravenous administration in acute myocardial infarction: Double-blind randomized trial. Br Med J 1983; 286:1107–1108.

    CAS  Google Scholar 

  159. Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Br J Clin Pharmacol 1986; 21:197S-204S.

    Google Scholar 

  160. Crea F, Deanfield J, Crean P, et al. Effects of verapamil in preventing early postinfarction angina and reinfarction. Am J Cardiol 1985; 55:900–904.

    PubMed  CAS  Google Scholar 

  161. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. N Engl J Med 1986; 315:423–429.

    PubMed  CAS  Google Scholar 

  162. Yusuf S, Furberg C. Effect of acute or chronic administration of calcium antagonists on mortality following myocardial infarction (abstr). J Am Coll Cardiol 1987; 9:24A.

    Google Scholar 

  163. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335–371.

    PubMed  CAS  Google Scholar 

  164. Hearse DJ: Critical distinctions in the modification of myocardial cell injury. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984; 129–145.

    Google Scholar 

  165. Opie LH, Coetzee WA. Are calcium ions involved in the genesis of early ischemic ventricular arrhythmias? In: Hearse D, Manning A, Janse M, eds. Life-Threatening Arrhythmias During Ischemia and Infarction. New York: Raven Press, 1987; 63–75.

    Google Scholar 

  166. Thandroyen FT. Protective action of calcium channel antagonist agents against ventricular fibrillation in isolated perfused rat heart. J Mol Cell Cardiol 1982; 14:21–32.

    PubMed  CAS  Google Scholar 

  167. Clusin WT, Bristow MR, Bain DS, et al. The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. Circ Res 1982; 50:518–526.

    PubMed  CAS  Google Scholar 

  168. Coetzee WA, Dennis SC, Opie LH, et al: Calcium channel blockers and early ischemic ventricular arrhythmias: Electrophysiological versus anti-ischemic effects. J Mol Cell Cardiol 1987; 19(Suppl 2):77–97.

    PubMed  CAS  Google Scholar 

  169. Lubbe WF, Podzuweit T, Daries PS, et al. The role of cyclic adenosine monophosphate in adrenergic effects on vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest 1978; 61:1260–1269.

    PubMed  CAS  Google Scholar 

  170. Opie LH, Nathan D, Lubbe WF. Biochemical aspects of arrhythmogenesis and ventricular fibrillation. Am J Cardiol 1979; 43:131–148.

    PubMed  CAS  Google Scholar 

  171. Opie LH, Muller C, Nathan D, et al. Evidence for role of cyclic AMP as second messenger of arrhythmogenic effects of beta-stimulation. Adv Cyclic Nucleotide Res 1980; 12:63–69.

    PubMed  CAS  Google Scholar 

  172. Thandroyen FT, Higginson L, Opie LH, et al. The influence of verapamil and its isomers on vulnerability to ventricular fibrillation during acute myocardial ischemia and adrenergic stimulation in isolated rat heart. J Mol Cell Cardiol 1986; 18:645–649.

    PubMed  CAS  Google Scholar 

  173. Nayler WG, Panagiotopoulos S, Elz JS, et al. Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. Am J Cardiol 1987; 59:75B–83B.

    PubMed  CAS  Google Scholar 

  174. Sievers RE, Rashid T, Garrett J, et al. Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits. Cardiovasc Drugs Ther 1987; 1:65–69.

    PubMed  CAS  Google Scholar 

  175. Hugenholtz PG, Serruys PW, Fleckenstein A, et al. Why Ca2+ antagonists will be most useful before or during early myocardial ischaemia and not after infarction has been established. Eur Heart J 1986; 7:270–278.

    PubMed  CAS  Google Scholar 

  176. Murakami T, Hess OM, Krayenbuehl HP. Left ventricular function before and after diltiazem in patients with coronary artery disease. J Am Coll Cardiol 1985; 5:723–730.

    CAS  Google Scholar 

  177. Yoon SB, McMillin-Wood JB, Michael LH, et al. Protection of canine cardiac mitochondrial function by verapamil-cardioplegia during ischemic arrest. Circ Res 1965; 56:704–708.

    Google Scholar 

  178. Bourdillon PD, Poole-Wilson PA. The effects of verapamil, quiescence, and cardioplegia on calcium exchange and mechanical function in ischemic rabbit myocardium. Circ Res 1982; 50:360–368.

    PubMed  CAS  Google Scholar 

  179. Bersohn MM, Shine KI. Verapamil protection of ischemic isolated rabbit heart: Dependence on pretreatment. J Mol Cell Cardiol 1983; 15:659–671.

    PubMed  CAS  Google Scholar 

  180. Henry PD, Shuchleib R, Davis J, et al. Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol 1977; 233:H677–H684.

    PubMed  CAS  Google Scholar 

  181. Cheung JY, Leaf A, Bonventre JV: Mechanism of protection by verapamil and nifedipine from anoxic injury in isolated cardiac myocytes. Am J Physiol 1984; 246:C323–C329.

    PubMed  CAS  Google Scholar 

  182. Hamm CW, Opie LH. Protection of infarcting myocardium by slow channel inhibitors. Comparative effects of verapamil, nifedipine, and diltiazem in the coronary-ligated, isolated working rat heart. Circ Res 1983; 52(Suppl I):129–138.

    CAS  Google Scholar 

  183. Kenmure ACF, Scruton JH. A double-blind controlled trial of the anti-anginal efficacy of nifedipine compared with propranolol. Br J Clin Pract 1980; (Suppl 8):49–52.

    Google Scholar 

  184. Humen DP, O’Brien P, Purves P, et al. Effort angina with adequate beta-receptor blockade: Comparison with diltiazem alone and in combination. J Am Coll Cardiol 1986; 7:329–335.

    PubMed  CAS  Google Scholar 

  185. Khurmi NS, Raftery EB. A comparison of nine calcium ion antagonists and propranolol: Exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris. Eur J Clin Pharmacol 1987; 32:539–548.

    PubMed  CAS  Google Scholar 

  186. Oakley GDG, Fox KM, Dargie HJ, et al. Objective assessment of treatment in severe angina. Br Med J 1979; i;1540.

    Google Scholar 

  187. Mauritson DR, Johnson SM, Winniford MD, et al. Verapamil for unstable angina at rest: A short-term randomized, double-blind study. Am Heart J 1983; 106:652–658.

    PubMed  CAS  Google Scholar 

  188. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319:385–392.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Cape Town, Cape Town, South Africa

    Lionel H. Opie MD, PhD, FRCP (Professor of Medicine, Consultant Professor)

  2. Division of Cardiology, Stanford University Medical Center, Stanford, California, USA

    Lionel H. Opie MD, PhD, FRCP (Professor of Medicine, Consultant Professor)

  3. Heart Research Unit, University of Cape Town, South Africa

    William A. Coetzee DSc (Principal Scientific Investigator)

Authors
  1. Lionel H. Opie MD, PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William A. Coetzee DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Opie, L.H., Coetzee, W.A. (1989). Use and Comparative Properties of the Three Prototypical Calcium Antagonists in Ischemic Heart Disease, Including Recommendations Based on an Analysis of 41 Trials. In: Clinical Use of Calcium Channel Antagonist Drugs. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0863-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0863-8_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8208-2

  • Online ISBN: 978-1-4613-0863-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation